Prediction of psychosis in adolescents and young adults at high risk: Results from the prospective European prediction of psychosis study

Archives of General Psychiatry

Volumn 67, Issue 3, 2010, Pages 241-251

  Ruhrmann, Stephan ^a   Schultze Lutter, Frauke ^a   Salokangas, Raimo K R ^b   Heinimaa, Markus ^b   Linszen, Don ^c   Dingemans, Peter ^c   Birchwood, Max ^d   Patterson, Paul ^d   Juckel, Georg ^e,f   Heinz, Andreas ^f   Morrison, Anthony ^g   Lewis, Shôn ^g   Graf Von Reventlow, Heinrich ^a   Klosterkötter, Joachim ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e RUHR UNIVERSITY BOCHUM   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BASIC SYMPTOM COGNITIVE DISTURBANCE CRITERION; CLINICAL ASSESSMENT; CLINICAL TRIAL; COGNITIVE DEFECT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE COURSE; EDUCATION; FEMALE; FINLAND; FOLLOW UP; FUNCTIONAL ASSESSMENT; GERMANY; HIGH RISK POPULATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NETHERLANDS; OUTPATIENT DEPARTMENT; PREDICTION; PROGNOSIS; PROSPECTIVE STUDY; PSYCHOSIS; RISK ASSESSMENT; SCHIZOTYPAL PERSONALITY DISORDER; SENSITIVITY AND SPECIFICITY; SLEEP DISORDER; SYMPTOM; THOUGHT DISORDER; ULTRA HIGH RISK CRITERION; UNITED KINGDOM;

ADULT; AMBULATORY CARE; DISEASE PROGRESSION; EARLY DIAGNOSIS; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; PROGNOSIS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISK ASSESSMENT; RISK FACTORS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 77649201030     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2009.206     Document Type: Article

References (81)

1. World Health Organization. Prevention of Mental Disorders: Effective Interventions and Policy Options. Geneva, Switzerland: World Health Organization; 2004.
2. Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine JP, Angermeyer MC, Bernert S, de Girolamo G, Morosini P, Polidori G, Kikkawa T, Kawakami N, Ono Y, Takeshima T, Uda H, Karam EG, Fayyad JA, Karam AN, Mneimneh ZN, Medina-Mora ME, Borges G, Lara C, de Graaf R, Ormel J, Gureje O, Shen Y, Huang Y, Zhang M, Alonso J, Haro JM, Vilagut G, Bromet EJ, Gluzman S, Webb C, Kessler RC, Merikangas KR, Anthony JC, Von Korff MR, Wang PS, Brugha TS, Aguilar-Gaxiola S, Lee S, Heeringa S, Pennell BE, Zaslavsky AM, Ustun TB, Chatterji S;WHO World Mental Health Survey Consortium. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA. 2004;291(21):2581-2590.
3. McGorry PD, Killackey EJ. Early intervention in psychosis: a new evidence based paradigm. Epidemiol Psichiatr Soc. 2002;11(4):237-247.
4. Mrazek PJ, Haggerty HJ. Reducing Risks for Mental Disorders: Frontiers for Preventive Research. Washington, DC: Academy Press; 1994.
5. Klosterkötter J, Ruhrmann S, Schultze-Lutter F, Salokangas RK, Linszen D, Birchwood M, Juckel G, Morrison A, Vazquez-Barquero JL, Hambrecht M, von Reventlow H. The European Prediction of Psychosis Study (EPOS): integrating early recognition and intervention in Europe. World Psychiatry. 2005;4(3):161-167.
6. Klosterkötter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry. 2001;58(2):158-164.
7. Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, Rakkar A. Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull. 1996;22(2):283-303.
8. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res. 2004;67(2-3):131-142.
9. Huber G. The concept of substrate-close basic symptoms and its significance for the theory and therapy of schizophrenic diseases [in German]. Nervenarzt. 1983;54(1):23-32.
10. Häfner H, Maurer K, Löffler W, an der Heiden W, Munk-Jorgensen P, Hambrecht M, Riecher-Rössler A. The ABC Schizophrenia Study: a preliminary overview of the results. Soc Psychiatry Psychiatr Epidemiol. 1998;33(8):380-386.
11. Köhn D, Niedersteberg A, Wieneke A, Bechdolf A, Pukrop R, Ruhrmann S, Schultze-Lutter F, Maier W, Klosterkötter J. Early course of illness in first episode schizophrenia with long duration of untreated illness: a comparative study [in German]. Fortschr Neurol Psychiatr. 2004;72(2):88-92.
12. Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull. 1996;22(2):353-370.
13. Miller TJ, McGlashan TH, Woods SW, Stein K, Driesen N, Corcoran CM, Hoffman R, Davidson L. Symptom assessment in schizophrenic prodromal states. Psychiatr Q. 1999;70(4):273-287.
14. Yung AR, Phillips LJ, Yuen HP, Francey SM, McFarlane CA, Hallgren M, McGorry PD. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr Res. 2003;60(1):21-32.
15. Miller TJ, McGlashan TH, Rosen JL, Somjee L, Markovich PJ, Stein K, Woods SW. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry. 2002;159(5):863-865.
16. Yung AR, Stanford C, Cosgrave E, Killackey E, Phillips L, Nelson B, McGorry PD. Testing the Ultra High Risk (prodromal) criteria for the prediction of psychosis in a clinical sample of young people. Schizophr Res. 2006;84(1):57-66.
17. Haroun N, Dunn L, Haroun A, Cadenhead KS. Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophr Bull. 2006;32(1):166-178.
18. Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, Seidman LJ, Perkins D, Tsuang M, McGlashan T, Heinssen R. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry. 2008;65(1):28-37.
19. Lencz T, Smith CW, Auther AM, Correll CU, Cornblatt BA. The assessment of "prodromal schizophrenia": unresolved issues and future directions. Schizophr Bull. 2003;29(4):717-728.
20. Broome MR, Woolley JB, Johns LC, Valmaggia LR, Tabraham P, Gafoor R, Bramon E, McGuire PK. Outreach and support in south London (OASIS): implementation of a clinical service for prodromal psychosis and the at risk mental state. Eur Psychiatry. 2005;20(5-6):372-378.
21. Yung AR, Nelson B, Stanford C, Simmons MB, Cosgrave EM, Killackey E, Phillips LJ, Bechdolf A, Buckby J, McGorry PD. Validation of "prodromal" criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up. Schizophr Res. 2008;105(1-3):10-17.
22. Schultze-Lutter F. Subjective symptoms of schizophrenia in research and the clinic: the basic symptom concept. Schizophr Bull. 2009;35(1):5-8.
23. Schultze-Lutter F, Klosterkötter J, Picker H, Steinmeyer E, Ruhrmann S. Predicting first-episode psychosis by basic symptom criteria. Clin Neuropsychiatry. 2007; 4(1):11-22.
24. McGorry PD, Yung AR, Bechdolf A, Amminger P. Back to the future: predicting and reshaping the course of psychotic disorder. Arch Gen Psychiatry. 2008; 65(1):25-27.
25. Schultze-Lutter F, Klosterkötter J. Bonn Scale for the Assessment of Basic Symptoms: Prediction List. Cologne, Germany: University of Cologne; 2002.
26. McGlashan TH, Miller TJ, Woods SW, Rosen JL, Hoffman RE, Davidson L. Structured Interview for Prodromal Syndromes, Version 3.0. New Haven, CT: PRIME Research Clinic, Yale School of Medicine; 2001.
27. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
28. Hall RC. Global assessment of functioning: a modified scale. Psychosomatics. 1995;36(3):267-275.
29. Hall RC, Parks J. The modified global assessment of functioning scale: addendum. Psychosomatics. 1995;36(4):416-417.
30. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
31. Beck AT. The Beck Depression Inventory. San Antonio, TX: The Psychological Cooperation; 1978.
32. World Health Organization. Composite International Diagnostic Interview, Core Version 1.1. Arlington, VA: American Psychiatric Publishing; 1993.
33. Salokangas RKR, Suomela T. EPOS Basic Data Form. Turku, Finland: University of Turku; 2002.
34. Schultze-Lutter F, Addington J, Ruhrmann S, Klosterkötter J. Schizophrenia Proneness Instrument: Adult Version. Rome, Italy: Giovanni Fioriti; 2007.
35. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders. Arlington, VA: American Psychiatric Publishing; 1997.
36. Jewell NP. Statistics for Epidemiology. Boca Raton, FL: Chapman & Hall / CRC; 2004.
37. Hosmer WD, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. New York, NY: Wiley & Sons; 1999.
38. Twisk JWR. Applied Multilevel Analysis. Cambridge, England: Cambridge University Press; 2006.
39. Parmar MKB, Machin D. Survival Analysis: A Practical Approach. Chichester, England: John Wiley & Sons; 1995.
40. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York, NY: John Wiley & Sons; 2000.
41. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version 2.2. http://www.OpenEpi.com. Updated November 2007; Accessed January 20, 2008.
42. Kirkbride JB, Fearon P, Morgan C, Dazzan P, Morgan K, Tarrant J, Lloyd T, Holloway J, Hutchinson G, Leff JP, Mallett RM, Harrison GL, Murray RM, Jones PB. Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AeSOP study. Arch Gen Psychiatry. 2006;63(3):250-258.
43. Riecher-Rössler A, Gschwandtner U, Aston J, Borgwardt S, Drewe M, Fuhr P, Pfluger M, Radu W, Schindler C, Stieglitz RD. The Basel early-detection-ofpsychosis (FEPSY)-study: design and preliminary results. Acta Psychiatr Scand. 2007;115(2):114-125.
44. Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Cannon T, Ventura J, McFarlane W, Perkins DO, Pearlson GD, Woods SW. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29(4):703-715.
45. Prognostic factors for high-grade malignant glioma: development of a prognostic index, a report of the Medical-Research Council Brain-Tumor Working Party. J Neurooncol. 1990;9(1):47-55.
46. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2008;70(2):510-514.
47. Briggs A, Spencer M, Wang H, Mannino D, Sin DD. Development and validation of a prognostic index for health outcomes in chronic obstructive pulmonary disease. Arch Intern Med. 2008;168(1):71-79.
48. Sackett DL, Strauss SE, Richardson WS, Haynes RB. Evidence-Based Medicine: How to Practice and Teach EBM. Edinburgh, Scotland: Churchill Livingstone; 2000.
49. Hennekens CH, Buring JE. Epidemiology in Medicine. New York, NY: Little, Brown and Co; 1987.
50. Corcoran C, Malaspina D, Hercher L. Prodromal interventions for schizophrenia vulnerability: the risks of being "at risk". Schizophr Res. 2005;73(2-3):173-184.
51. Addington J, Cadenhead KS, Cannon TD, Cornblatt B, McGlashan TH, Perkins DO, Seidman LJ, Tsuang M, Walker EF, Woods SW, Heinssen R; North American Prodrome Longitudinal Study. North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. Schizophr Bull. 2007;33(3):665-672.
52. Jackson HJ, McGorry PD, Dudgeon P. Prodromal symptoms of schizophrenia in first-episode psychosis: prevalence and specificity. Compr Psychiatry. 1995;36(4):241-250.
53. Subotnik KL, Nuechterlein KH, Green MF, Horan WP, Nienow TM, Ventura J, Nguyen AT. Neurocognitive and social cognitive correlates of formal thought disorder in schizophrenia patients. Schizophr Res. 2006;85(1-3):84-95.
54. Pukrop R, Ruhrmann S, Schultze-Lutter F, Bechdolf A, Brockhaus-Dumke A, Klosterkötter J. Neurocognitive indicators for a conversion to psychosis: comparison of patients in a potentially initial prodromal state who did or did not convert to a psychosis. Schizophr Res. 2007;92(1-3):116-125.
55. Marengo JT, Harrow M, Laninkettering I, Wilson A. Evaluating bizarre-idiosyncratic thinking: a comprehensive index of positive thought-disorder. Schizophr Bull. 1986;12(3):497-511.
56. Monti JM, Monti D. Sleep disturbance in schizophrenia. Int Rev Psychiatry. 2005;17(4):247-253.
57. Tan HY, Ang YG. First-episode psychosis in the military: a comparative study of prodromal symptoms. Aust N Z J Psychiatry. 2001;35(4):512-519.
58. Yung AR, McGorry PD. The initial prodrome in psychosis: descriptive and qualitative aspects. Aust N Z J Psychiatry. 1996;30(5):587-599.
59. Miller P, Byrne M, Hodges A, Lawrie SM, Owens DG, Johnstone EC. Schizotypal components in people at high risk of developing schizophrenia: early findings from the Edinburgh High-Risk Study. Br J Psychiatry. 2002;180:179-184.
60. Mason O, Startup M, Halpin S, Schall U, Conrad A, Carr V. Risk factors for transition to first episode psychosis among individuals with 'at-risk mental states'. Schizophr Res. 2004;71(2-3):227-237.
61. Nordentoft M, Thorup A, Petersen L, Ohlenschlaeger J, Melau M, Christensen TO, Krarup G, Jorgensen P, Jeppesen P. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial: a randomized clinical trial of integrated treatment and standard treatment. Schizophr Res. 2006;83(1):29-40.
62. Addington J, Penn D, Woods SW, Addington D, Perkins DO. Social functioning in individuals at clinical high risk for psychosis. Schizophr Res. 2008;99(1-3):119-124.
63. Häfner H, Nowotny B, Löffler W, an der Heiden W, Maurer K. When and how does schizophrenia produce social deficits? Eur Arch Psychiatry Clin Neurosci. 1995;246(1):17-28.
64. Cornblatt BA, Lencz T, Smith CW, Correll CU, Auther AM, Nakayama E. The schizophrenia prodrome revisited: a neurodevelopmental perspective. Schizophr Bull. 2003;29(4):633-651.
65. Corcoran C, Davidson L, Sills-Shahar R, Nickou C, Malaspina D, Miller T, McGlashan T. A qualitative research study of the evolution of symptoms in individuals identified as prodromal to psychosis. Psychiatr Q. 2003;74(4):313-332.
66. Norman RM, Scholten DJ, Malla AK, Ballageer T. Early signs in schizophrenia spectrum disorders. J Nerv Ment Dis. 2005;193(1):17-23.
67. Kessler RC, Barker PR, Colpe LJ, Epstein JF, Gfroerer JC, Hiripi E, Howes MJ, Normand SLT, Manderscheid RW, Walters EE, Zaslavsky AM. Screening for serious mental illness in the general population. Arch Gen Psychiatry. 2003;60(2):184-189.
68. Kessler RC, Andrews G, Colpe LJ, Hiripi E, Mroczek DK, Normand SLT, Walters EE, Zaslavsky AM. Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychol Med. 2002;32(6):959-976.
69. Friis S, Sundet K, Rund BR, Vaglum P, McGlashan TH. Neurocognitive dimensions characterising patients with first-episode psychosis. Br J Psychiatry Suppl. 2002;43:s85-s90.
70. Swanson CL Jr, Gur RC, Bilker W, Petty RG, Gur RE. Premorbid educational attainment in schizophrenia: association with symptoms, functioning, and neurobehavioral measures. Biol Psychiatry. 1998;44(8):739-747.
71. Cuesta MJ, Peralta V, Zarzuela A. Illness duration and neuropsychological impairments in schizophrenia. Schizophr Res. 1998;33(3):141-150.
72. Lencz T, Smith CW, Auther A, Correll CU, Cornblatt B. Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophr Res. 2004;68(1):37-48.
73. Sham PC, Jones P, Russell A, Gilvarry K, Bebbington P, Lewis S, Toone B, Murray R. Age at onset, sex, and familial psychiatric morbidity in schizophrenia: Camberwell Collaborative Psychosis Study. Br J Psychiatry. 1994;165(4):466-473.
74. Kendler KS, McGuire M, Gruenberg AM, Spellman M, O'Hare A, Walsh D. The Roscommon Family Study, II: the risk of nonschizophrenic nonaffective psychoses in relatives. Arch Gen Psychiatry. 1993;50(8):645-652.
75. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, Germano D, Bravin J, McDonald T, Blair A, Adlard S, Jackson H. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry. 2002;59(10):921-928.
76. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry. 2006;163(5):790-799.
77. Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J, Miller TJ, Hawkins KA, Marquez E, Lindborg SR, Tohen M, McGlashan TH. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry. 2003;54(4):453-464.
78. Ruhrmann S, Bechdolf A, Kühn KU, Wagner M, Schultze-Lutter F, Janssen B, Maurer K, Häfner H, Gaebel W, Möller HJ, Maier W, Klosterkötter J. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br J Psychiatry Suppl. 2007;191(suppl 51):S88-S95.
79. McGlashan TH. Psychosis treatment prior to psychosis onset: ethical issues. Schizophr Res. 2001;51(1):47-54.
80. Pajonk FG. Clinical trial design in schizophrenia: implications for clinical decisions. Curr Opin Psychiatry. 2005;18(6):692-699.
81. McGorry PD. Issues for DSM-V, clinical staging: a heuristic pathway to valid nosology and safer, more effective treatment in psychiatry. Am J Psychiatry. 2007;164(6):859-860.